Pay, Patriots And The Art of Promise: What Results Season Taught Us
Most of the biggest pharmaceutical companies that pay taxes in Europe or North America have told the world how they got on in 2017. So what, other than the corrective value of financial performance minutiae, did we learn?
You may also be interested in...
As pharma invests its bounty from last year's tax reform in stock buybacks, capital improvements and other investments, Sen. Cory Booker issues a report suggesting companies should lower drug prices instead, but does not offer recommendations for how that might be done.
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.